Allogeneic hematopoietic stem cell transplantation in non‐Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better-Reference-Cited by-同舟云学术

Allogeneic hematopoietic stem cell transplantation in non‐Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better

Published:2022-11-13 Issue:1 Volume:4 Page:258-261
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Rebmann Ekaterina¹²^ORCID,Nabergoj Mitja³,Grandjean Bastien¹,Stakia Paraskevi⁴,Stern Alix²⁵,Medinger Michael⁶^ORCID,Masouridi‐Levrat Stavroula⁴,Dantin Carole⁴,Schanz Urs⁷,Baldomero Helen⁶⁸,Passweg Jakob⁶⁵,Nair Gayathri⁷,Rovo Alicia¹^ORCID,Chalandon Yves⁴⁹

Affiliation:

1. Department of Hematology University Hospital of Bern (Inselspital) Bern Switzerland

2. Department of Oncology‐Hematology Hospital of Neuchâtel (RHNE) Neuchâtel Switzerland

3. Department of Hematology L'Hôpital Riviera‐Chablais Vaud‐Valais Switzerland

4. Department of Hematology Geneva University Hospitals (HUG) Genève Switzerland

5. Faculty of Medicine University of Basel Basel Switzerland

6. Department of Hematology University Hospital of Basel (USB) Basel Switzerland

7. Department of Hematology University Hospital of Zurich (UZH) Zürich Switzerland

8. SBST Data Registry OfficeUnivesiry Hospital of Basel Basel Switzerland

9. Faculty of Medicine University of Geneva Geneva Switzerland

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.614

Reference16 articles.

1. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma

2. Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

3. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas

4. Retrospective comparison of allogeneic vs autologous transplantation for diffuse large B-cell lymphoma with early relapse or primary induction failure

5. Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality